Amyloid-related imaging abnormalities (ARIA) are monitored by magnetic resonance imaging of the brain one to two times per year. The most common serious adverse reactions reported are: * ARIA-E edema of brain (35% of patients treated with Aduhelm vs 3% of patients treated with placebo) – Symptoms may include headache, changes in mental state, confusion, vomiting, nausea, tremor and gait disturbances. * Headache (21% vs 16%) * ARIA-H microhemorrhage or bleeding of brain (19% vs 7%) – Symptoms can include headache, one-sided weakness, vomiting, seizures, decreased level of consciousness, and neck stiffness. * ARIA-H superficial siderosis (hemosiderin) (15% vs 2%) * Fall (15% vs 12%) * Diarrhea (9% vs 7%) * Confusion/delirium/altered mental status/disorientation (8% vs 4%)
Aducanumab
Evolocumab
Alirocumab
Emapalumab
Tralokinumab
Olaratumab
Ustekinumab
Anifrolumab